

**AMENDMENTS TO THE CLAIMS**

This listing of the claims replaces all prior versions and listings:

1. (currently amended): A method for generating an immune response against one or more intracellular pathogens within warm-blooded animals, comprising:

(a) administering to a warm-blooded animal a ~~gene-delivery vehicle~~ vector construct comprising a polynucleotide encoding at least one immunogenic portion of an antigen obtained from an intracellular pathogen, wherein ~~gene-delivery vehicle~~ vector construct is selected from the group consisting of retroviral vectors, alphavirus vectors, parvovirus vectors, or eukaryotic layered vector initiation system vectors; and

(b) administering to said warm-blooded animal, prior to or subsequent to administration of said ~~gene-delivery vehicle~~ vector construct, at least one protein which comprises at least one immunogenic portion of an antigen obtained from said intracellular pathogen, such that an immune response against the intracellular pathogen is generated.

2. (original): The method according to claim 1, further comprising the step of administering an immunomodulatory cofactor.

3. (currently amended): The method according to claim 1, wherein said protein is administered prior to administration of said ~~gene-delivery vehicle~~ vector construct.

4. (original): The method according to claim 1, wherein said intracellular pathogen is virus and said antigen a viral antigen.

5. (previously presented): The method according to claim 4, wherein said virus is a hepatitis virus.

6 to 11. (canceled).

12. (currently amended): The method according to claim 1, wherein said ~~gene-delivery vehicle~~ vector construct is an alphavirus vector.

13. (currently amended): The method according to claim 1, wherein said ~~gene-delivery vehicle~~ vector construct is a eukaryotic layered vector initiation system vector.

14 to 25. (canceled).

26. (previously presented): The method according to claim 4, wherein said virus is a feline immunodeficiency virus (FIV) or a human immunodeficiency virus (HIV).

27. (currently amended): The method according to claim 1, wherein said ~~gene-delivery vehicle~~ vector construct is a retroviral vector.

28. (currently amended): The method according to claim 1, wherein said ~~gene-delivery vehicle~~ vector construct is a parvovirus vector.

29. (currently amended): The method according to claim 28, wherein said ~~gene-delivery vehicle~~ vector construct is an adeno-associated virus vector.

30. (canceled).